Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells

被引：8
|
作者：
De Martino, Maria Cristina [1 ]
van Koetsveld, Peter M. [1 ]
Feelders, Richard A. [1 ]
Lamberts, Steven W. J. [1 ]
de Herder, Wouter W. [1 ]
Colao, Annamaria [2 ]
Pivonello, Rosario [2 ]
Hofland, Leo J. [1 ]
机构：
[1] Erasmus MC, Div Endocrinol, Dept Internal Med, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands
[2] Univ Naples Federico II, Dipartimento Med Clin & Chirurg, Sez Endocrinol, Via S Pansini 5, I-80131 Naples, Italy
来源：
ENDOCRINE | 2016年 / 52卷 / 03期
关键词：
MAMMALIAN TARGET; MTOR PATHWAY; INHIBITOR; CANCER; TEMSIROLIMUS; MANAGEMENT; EVEROLIMUS; TUMORS;
D O I：
10.1007/s12020-015-0818-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：664 / 667
页数：4
相关论文
共 50 条
  • [1] Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells
    Maria Cristina De Martino
    Peter M. van Koetsveld
    Richard A. Feelders
    Steven W. J. Lamberts
    Wouter W. de Herder
    Annamaria Colao
    Rosario Pivonello
    Leo J. Hofland
    Endocrine, 2016, 52 : 664 - 667
  • [2] Mitotane treatment for adrenocortical carcinoma: an overview
    De Francia, S.
    Ardito, A.
    Daffara, F.
    Zaggia, B.
    Germano, A.
    Berruti, A.
    Di Carlo, F.
    MINERVA ENDOCRINOLOGICA, 2012, 37 (01) : 9 - 23
  • [3] Adjuvant mitotane treatment for adrenocortical carcinoma
    Terzolo, Massimo
    Angeli, Alberto
    Fassnacht, Martin
    Daffara, Fulvia
    Tauchmanova, Libuse
    Conton, Pier Antonio
    Rossetto, Ruth
    Buci, Lisa
    Sperone, Paola
    Grossrubatscher, Erika
    Reimondo, Giuseppe
    Bollito, Enrico
    Papotti, Mauro
    Saeger, Wolfgang
    Hahner, Stefanie
    Koschker, Ann-Cathrin
    Arvat, Emanuela
    Ambrosi, Bruno
    Loli, Paola
    Lombardi, Gaetano
    Mannelli, Massimo
    Bruzzi, Paolo
    Mantero, Franco
    Allolio, Bruno
    Dogliotti, Luigi
    Berruti, Alfredo
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (23): : 2372 - 2380
  • [4] Sunitinib monotherapy instead of mitotane combination therapy for the treatment of refractory adrenocortical carcinoma
    Zhuang, Jintao
    Wang, Daohu
    Wu, Rongpei
    Tu, Xiangan
    Chen, Yu
    Qiu, Shaopeng
    INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (11) : 1079 - 1081
  • [5] Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells
    Poli, Giada
    Guasti, Daniele
    Rapizzi, Elena
    Fucci, Rossella
    Canu, Letizia
    Bandinelli, Alessandra
    Cini, Nicoletta
    Bani, Daniele
    Mannelli, Massimo
    Luconi, Michaela
    ENDOCRINE-RELATED CANCER, 2013, 20 (04) : 537 - 550
  • [6] Pharmacological profile and effects of mitotane in adrenocortical carcinoma
    Corso, Claudia Rita
    Acco, Alexandra
    Bach, Camila
    Ribeiro Bonatto, Sandro Jose
    de Figueiredo, Bonald Cavalcante
    de Souza, Lauro Mera
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (07) : 2698 - 2710
  • [7] Practical treatment using mitotane for adrenocortical carcinoma
    Terzolo, Massimo
    Zaggia, Barbara
    Allasino, Barbara
    De Francia, Silvia
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2014, 21 (03) : 159 - 165
  • [8] New perspectives for mitotane treatment of adrenocortical carcinoma
    Puglisi, S.
    Calabrese, A.
    Basile, V
    Pia, A.
    Reimondo, G.
    Perotti, P.
    Terzolo, M.
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 34 (03)
  • [9] Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells
    Villa, R
    Orlandi, L
    Berruti, A
    Dogliotti, L
    Zaffaroni, N
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1999, 14 (01) : 133 - 138
  • [10] Mitotane treatment for recurrent adrenocortical carcinoma following adrenalectomy
    Garcia Dominguez, Paula
    Dibella, Andrea
    VETERINARY RECORD CASE REPORTS, 2023, 11 (04):
12345